The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics
Abstract
BACKGROUND: A new benzodiazepine, remimazolam, metabolized by tissue esterases to an inactive compound, CNS 7054, has been developed to permit a fast onset, a short and more predictable duration of sedative action, and a more rapid recovery profile than with currently available benzodiazepines. We report on the safety and efficacy of the first human study. METHODS: A phase I, single-center, double-blind, placebo- and active-controlled, randomized, single-dose escalation study was conducted. Up to 10 cohorts of healthy subjects were scheduled to receive a single 1-minute IV infusion of remimazolam, midazolam, or placebo. In the 10 possible cohorts, remimazolam doses were from 0.01 to 0.35 mg/kg. In cohorts 1 to 3, 6 subjects received remimazolam and 1 placebo. From cohort 4 onward, an additional 3 subjects in each cohort received midazolam (0.075 mg/kg). Safety, pharmacokinetics, and pharmacodynamics were measured. A stop criterion of loss of consciousness for >5 minutes in >50% of subjects was predefined. RESULTS: The stop criterion was reached in cohort 9 (0.30 mg/kg remimazolam) so that 81 subjects were enrolled. Remimazolam was well tolerated in all dose cohorts, and no serious adverse events (AEs) were reported. Three AEs of mild (Spo(2) 85%-88%) hemoglobin desaturation (2 in the remimazolam groups and 1 in the midazolam group) resolved spontaneously, and 1 AE of moderate hemoglobin desaturation (Spo(2) 75%) resolved with a chin lift in the highest remimazolam dose group. No supplemental oxygen or manual ventilation was required. Vital signs remained stable throughout, although there was an increase in heart rate 2 minutes postdose for both remimazolam and midazolam. There were no reports of hypo- or hypertension. The pharmacokinetic behavior of remimazolam was linear and its systemic clearance approximately 3 times that of midazolam. Clearance was essentially independent of body weight. A rapid onset and dose-dependent sedation was observed after administration of remimazolam at 0.05 mg/kg and higher. Remimazolam (0.075 to 0.20 mg/kg) induced peak sedation levels similar to or higher than those achieved with midazolam (0.075 mg/kg). Median recovery times after approximately equieffective doses of remimazolam (0.10 and 0.15 mg/kg) and midazolam (0.075 mg/kg) were 10 and 40 minutes, respectively. CONCLUSIONS: Remimazolam provided sedation with rapid onset and offset, and was well tolerated. There was no supplemental oxygen or ventilation required. On the basis of these data, further studies on the potential utility of remimazolam for sedation/anesthesia are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Difficult tracheal intubation: a retrospective study
SAMSOON, G. L. T., & YOUNG, J. R. B. (1987) · Anaesthesia · doi:10.1111/j.1365-2044.1987.tb04039.x · Cited by 1,584
Validity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
Kilpatrick (2007) · doi:10.1097/01.anes.0000267503.85085.c0 · Cited by 381
Wiltshire, H. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318241f68a · Cited by 215 · cited 1×
“We provide the safety and efficacy results, and an accompanying study published in this issue of the Journal will provide the detailed PK and PD of this compound.(7)”
MethodSelf-citationBispectral index monitoring of sedation during endoscopy
Bower, A. L., Ripepi, A., Dilger, J., Boparai, N., Brody, F. J., & Ponsky, J. L. (2000) · Gastrointestinal Endoscopy · doi:10.1067/mge.2000.107284 · Cited by 171
Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep
Upton, R. N., Martinez, A., & Grant, C. M. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep269 · Cited by 70
Upton, R. N., Martinez, A. M., & Grant, C. M. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.228 · Cited by 57
Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep
Upton, R. N., Somogyi, A. A., Martinez, A. M., Colvill, J., & Grant, C. M. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq260 · Cited by 49
ALLEN’S TEST AND SYSTOLIC ARTERIAL PRESSURE IN THE THUMB
Husum, B., & Berthelsen, P. G. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.6.635 · Cited by 45
Cited by
Doi, M., Morita, K., Takeda, J., Sakamoto, A., Yamakage, M., & Suzuki, T. (2020) · Journal of Anesthesia · doi:10.1007/s00540-020-02788-6 · Cited by 484
Schüttler, J., Eisenried, A., Lerch, M., Fechner, J., Jeleazcov, C., & Ihmsen, H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003103 · Cited by 338
Pastis, N. J., Yarmus, L. B., Schippers, F., Ostroff, R., Chen, A., Akulian, J., Wahidi, M., Shojaee, S., Tanner, N. T., Callahan, S. P., et al. (2019) · Chest · doi:10.1016/j.chest.2018.09.015 · Cited by 307
Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent
Kilpatrick, G. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690875 · Cited by 262
Self-citationRemimazolam: pharmacological characteristics and clinical applications in anesthesiology
Kim, K. M. (2022) · Anesthesia and Pain Medicine · doi:10.17085/apm.21115 · Cited by 257
Metadata
- Authors
- Antonik, L. J., Goldwater, D. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M.
- Venue
- Anesthesia & Analgesia
- Published
- 2012-08
- Volume
- 115
- Issue
- 2
- Pages
- 274-283
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W2324884202
- Cited by
- 374
- References
- 9
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics. https://app.cochat.ai/papers/10.1213/ane.0b013e31823f0c28
- The paper
- Antonik, L. J., Goldwater, D. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012). A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0b013e31823f0c28
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.